AR 2.3.6 - 0% 6 B IO D E G R A D A T IO N (BOD/COD) T E S T S U B S T A N C E __________________________________________________ Identity: A mixture containing perfluorooctanesulfonate, which m ay a lso be referred to a s P F O S , FC-95, or a s a com ponent of FC -20 6C E . (1Octanesulfonic acid) (C A S # 2795-39-3).

Electronically Served 9/22/2017 10:26 PM Hennepin County, MN 27-CV-10-28862 Filed in Fourth Judicial District Court 11/17/2017 7:07 PM Hennepin County, MN STATE OF MINNESOTA DISTRICT COURT FOR THE COUNTY OF HENNEPIN FOURTH JUDICIAL DISTRICT CIVIL ACTION NO. 27-CV-10-28862 STATE OF MINNESOTA, et al. v. 3M COMPANY EXPERT REPORT OF KIRK W.

Overview FACT SHEET PFOA & PFOS Drinking Water Health Advisories EPA has e sta b lis h e d h e a lth a d v is o rie s fo r PFOA and PFOS based on th e a g e n cy's a sse ssm e n t o f th e la te s t p e e r-re v ie w e d science to p ro v id e d rin k in g w a te r s yste m o p e ra to rs , and s ta te , trib a l and local o ffic ia ls w h o have th e p rim a ry re s p o n s ib ility fo r o ve rse e in g th e se system s, w ith in fo rm a tio n on th e h e a lth risks o f th e s e c h e m ic a ls , so th e y can ta k e th e a p p ro p ria te a c tio n s t o p r o t e c t t h e ir re s id e n ts .

Fraunhofer ITEM Final Report 01 G 00 0 02 [Appendices G] Page 1 of 12 28 Day Repeated Dermal Contact Study of 3M Test Articles in Sprague-Dawley Rats _____________________________________________________________________________________________________________ Appendix G: Amendments and Deviations (Copies) Fraunhofer ITEM Final Report 01 G 00 0 02 [Appendices G] Page 2 of 12 28 Day Repeated Dermal Contact Study of 3M Test Articles in Sprague-Dawley Rats _____________________________________________________________________________________________________________ Fraunhofer ITEM Final Report 01 G 00 0 02 [Appendices G] Page 3 of 12 28 Day Repeated Dermal Contact Study of 3M Test Articles in Sprague-Dawley Rats _____________________________________________________________________________________________________________ Fraunhofer ITEM Final Report 01 G 00 0 02 [Appendices G] Page 4 of 12 28 Day Repeated Dermal Contact Study of 3M Test Articles in Sprague-Dawley Rats _____________________________________________________________________________________________________________ Fraunhofer ITEM Final Report 01 G 00 0 02 [Appendices G] Page 5 of 12 28 Day Repeated Dermal Contact Study of 3M Test Articles in Sprague-Dawley Rats _____________________________________________________________________________________________________________ Fraunhofer ITEM Final Report 01 G 00 0 02 [Appendices G] Page 6 of 12 28 Day Repeated Dermal Contact Study of 3M Test Articles in Sprague-Dawley Rats _____________________________________________________________________________________________________________ Fraunhofer ITEM Final Report 01 G 00 0 02 [Appendices G] Page 7 of 12 28 Day Repeated Dermal Contact Study of 3M Test Articles in Sprague-Dawley Rats _____________________________________________________________________________________________________________ Fraunhofer ITEM Final Report 01 G 00 0 02 [Appendices G] Page 8 of 12 28 Day Repeated Dermal Contact Study of 3M Test Articles in Sprague-Dawley Rats _____________________________________________________________________________________________________________ Fraunhofer ITEM Final Report 01 G 00 0 02 [Appendices G] Page 9 of 12 28 Day Repeated Dermal Contact Study of 3M Test Articles in Sprague-Dawley Rats _____________________________________________________________________________________________________________ Fraunhofer ITEM Final Report 01 G 00 0 02 [Appendices G] Page 10 of 12 28 Day Repeated Dermal Contact Study of 3M Test Articles in Sprague-Dawley Rats _____________________________________________________________________________________________________________ Fraunhofer ITEM Final Report 01 G 00 0 02 [Appendices G] Page 11 of 12 28 Day Repeated Dermal Contact Study of 3M Test Articles in Sprague-Dawley Rats _____________________________________________________________________________________________________________ Fraunhofer ITEM Final Report 01 G 00 0 02 [Appendices G] Page 12 of 12 28 Day Repeated Dermal Contact Study of 3M Test Articles in Sprague-Dawley Rats _____________________________________________________________________________________________________________

StudyTide FC-143:TWoYEARORAL TOXIITY-ONCOSGTUEDNYICNIRATTYS PEER RevoFiOveanwes Authors Peter C.

2972508 PlasticsEurope Fluoropotymers Product Group E-Mail: Mbaua.bund.de You can contact our Data Protection Officer under the postal address above or by e-mail to baua.bund.de.

2965204 From: 5.1.2e <=1@cefic.be> Sent: dinsdag 1 december 2020 15:19 To: restrictiePFAS <MEMPrivm.nl>; MMW:I a.bund.de; ISCOMIE :emi.se; MVnalt_cc Cc: 51 2e - PlasticsEurope <:Mal olasticseurope.org>;M:= AGC Chemicals Europe Ltd <=1IEMap,Lc n>;MilEM-- QuintEssence Consulting rm jltaccorn> Subject: Consultation on Proposed Comprehensive Restriction/Ban for All Per and Polyfluoroalkyl /k (kPr II AS) Substances Dear all Past few weeks several of our members have received multiple questionnaires seeking to collect data to assess potential impacts and unintended consequences of a comprehensive PFAS restriction.

B ' a5 . ^ - a s 4^^ ^.

The exemption application of perfluorosulfonic acid(PFSA) resins and perfluorocarboxylic acid(PFCA) resins and ion exchange membranes for chlor-alkali industry Chlor-alkali industry is the largest sector in the modern chemical industry.

AR226-2565 EGA Technical Subgroup Monitoring Landfill Monitoring and Exposure Summ Goal for Today Understand the contribiition of landfills PFOA levels in the environment Environmental Assessment F Manufacturing Facilities/Land 1.

AR226-2673 63 ^S^^^1^^W^^%%^^%%!

MOLYKOTE Specialty Lubricants for HV connectors Lubricants for high-voltage connectors to ensure proper sealing performance and consistent electrical conductivity over time Ensure reliability of high-voltage connectors in EVs The number of high-voltage connectors in electrified vehicles has increased significantly.

AR226-2700 AR226-2700 TORONTO WORKSHOP MATERIALS September 13-14,2004 John Gannon DuPont Central Research & Develop Wilmington, DE of in the Is the Sources?

CLP Reglerna i CLP om klassificering och mrkning gller inte lkemedel men dremot ingredienser till lkemedel.

Section III - Non-Confidential Comment Biotherapeutic filters are process filters used during the manufacturing of bio-therapeutic drug products or samples such as therapeutic replacement of enzymes, antibodies, blood, derivatives of plasma, and biopharmaceuticals.